{"entity":{"id":"nct07833241","kind":"trial","name":"Surufatinib in Combination With Iparomlimab and Tuvonralimab Injection and AG Chemotherapy for Neoadjuvant Therapy of HRPC or BRPC","aka":["ZSPAC-22"],"tldr":"A phase 2 trial of gemcitabine + nab-paclitaxel, gemcitabine, capecitabine and fOLFIRINOX / mFOLFIRINOX in pancreatic cancer, run by Shanghai Zhongshan Hospital, not yet recruiting.","summary":"Surufatinib in Combination With Iparomlimab and Tuvonralimab Injection and AG Chemotherapy for Neoadjuvant Therapy of HRPC or BRPC is a phase 2, interventional study registered as NCT07833241 by Shanghai Zhongshan Hospital, with a registry enrolment figure of 56 participants, started 2026-09-01 and due to reach its primary completion in 2028-09-01. Interventions recorded: Surufatinib Plus Iparomlimab and Tuvonralimab and AG Chemotherapy; Gemcitabine plus Capecitabine; Modified FOLFIRINOX. Conditions listed: Borderline Resectable Pancreatic Cancer; High-Risk Resectable Pancreatic Cancer. Primary outcome: 12-month Event Free Survival (EFS) rate. Pancreatic eligibility wording from the registry: \"* Patients with high-risk resectable or borderline resectable pancreatic adenocarcinoma confirmed by histopathology or cytology\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07833241","url":"https://clinicaltrials.gov/study/NCT07833241"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["borderline-resectable-pdac","resectable-pdac"],"sections":[],"technologies":["cytotoxic-chemotherapy","platinum","topoisomerase-inhibitors"],"targets":[],"drugs":["gemcitabine-nab-paclitaxel","gemcitabine","capecitabine","folfirinox"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07833241","phase":"2","setting":"Neoadjuvant Surufatinib in Combination With Iparomlimab and Tuvonralimab Injection and AG Chemotherapy for High-risk Resectable or Borderline Resectable Pancreatic Cancer: a Single-arm, Single-center, Exploratory Clinical Study","sponsor":"Shanghai Zhongshan Hospital","enrolled":56,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07833241/","neighbours":{"cancer":[{"id":"borderline-resectable-pdac","kind":"cancer","name":"Borderline resectable pancreatic ductal adenocarcinoma","route":"/cancers/borderline-resectable-pdac/"},{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"folfirinox","kind":"drug","name":"FOLFIRINOX / mFOLFIRINOX","route":"/drugs/folfirinox/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"gemcitabine-nab-paclitaxel","kind":"drug","name":"Gemcitabine + nab-paclitaxel","route":"/drugs/gemcitabine-nab-paclitaxel/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}